Dr. Michael Jewett is recognized as one of the foremost oncologists in the world in the area of bladder cancer. He has been the Principal Investigator/Co-Principal Investigator on over 60 clinical trials leading to FDA or Health Canada approvals. He has reviewed Theralase’s Photo Dynamic Compound (PDC) technology and is looking forward to working with Theralase closely in their quest to commercialize their PDC technology to the ultimate benefit of bladder cancer patients.

1. Press Release
Renowned Oncologist Dr. Michael Jewett Joins Theralase’s Medical and Scientific
Advisory Board
Toronto, Ontario –January 29, 2013 -- Theralase Technologies Inc. (TSX-V: TLT) is pleased to announce
that effective January 15, 2013, Michael Jewett MD, FRCSC, FACS has elected to join its Medical and
Scientific Advisory Board.
Dr. Michael Jewett is currently a Professor of Surgery in the Division of Urology at the University of
Toronto, a member of the Department of Surgical Oncology at Princess Margaret Cancer Centre and of
the Division of Urology at the University Health Network. He is well known for his contributions in the
fields of technology assessment and image guided therapy, especially for minimally invasive treatment
of kidney and bladder cancer. He is internationally known for his contributions in the fields of bladder,
testis and kidney cancer fundamental and clinical research. For his valued contributions to the uro-
oncology field, in 2008, Dr. Jewett was awarded the Wyeth/CIHR Rx&D Clinical Research Chair in
Oncology. He also holds the Farquaharson Chair for Kidney Cancer Research.
Dr. Jewett has been the Principal Investigator/Co-Principal Investigator on over 60 Phase I-Phase III
clinical trials and the Lead Principal Investigator of several Cooperative Group Trials. These clinical trials
have primarily been focused on proving the safety, efficacy and clinical benefits of technology in the
destruction of cancer, with the ultimate gain of achieving Health Canada or FDA clinical approval.
He has recently served as Chairman of the Division of Urology at the University of Toronto and of
Urology at the University Health Network, which incorporates the Princess Margaret Cancer Centre,
one of the world's leading cancer centres. He is a recent Past-President of the Canadian Urology
Association and a member of many urological and surgical oncology societies; including the Scientific
Advisory Board of the Bladder Cancer Advocacy Network, the Medical Advisory and Research Board of
Bladder Cancer Canada, and Chair of the CIHR funded Kidney Cancer Research Network of Canada. Dr.
Jewett has been recognized for his lifetime achievements and contributions to Urology by the Canadian
Urological Association, the American Urological Association, the Societe Internationale d’Urologie and
the Society of Urologic Oncology.
Dr. Jewett stated, “I have been very impressed with the expertise of the Theralase team and with the
significant opportunity their Photo Dynamic Compounds (PDCs) present in the field of bladder cancer
treatment. I look forward to working with them closely in their quest to commercialize their PDC
technology to the ultimate benefit of bladder cancer patients, when the unmet need remains so
great”.
Roger Dumoulin-White, President and CEO, Theralase Technologies Inc. stated that, “We are elated to
have someone of Dr. Jewett’s calibre join Theralase’s Medical and Scientific Advisory Board to lead our
bladder cancer clinical research program. He has been actively engaged in clinical cancer research and
will prove to be an invaluable resource for helping to design our clinical protocols, in conjunction with
our research team, as we focus on our lead target, bladder cancer. With Dr. Jewett’s expert guidance,
we are confident that we will be able to complete the steps necessary to commence FDA Phase 1

2. Press Release
human clinical trials in 2013 with our lead Photo Dynamic Compound (PDC), where we will
demonstrate that Theralase possesses a highly effective and safe alternative treatment option to
patients, suffering from non-muscle invasive bladder cancer. Based on the clinical success of the PDC
technology in FDA Phase 1 human clinical trials, Theralase is expected to be granted FDA “Fast Track”
designation allowing an expedited priority review and approval process.”
According to the FDA, “Fast Track” is a process designed to facilitate the development and expedite the
review of drugs to treat serious diseases and fill an unmet medical need. The purpose is to get
important new drugs to the patient earlier.
About Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented,
superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase
technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural
muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo
Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when
light activated by Theralase’s proprietary and patented laser technology.
For further information please visit www.theralase.com , regulatory filings may be viewed by visiting
www.sedar.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to
update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts
responsibility for the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO
416-694-7246 ext. 225
rwhite@theralase.com
Kristina Hachey
Chief Financial Officer
416-694-7246 ext. 224
khachey@theralase.com
Arkady Mandel
Chief Scientific Officer
416-694-7246 ext. 242
amandel@theralase.com
Greg Bewsh
Director of Investor Relations

3. Press Release
416-694-7246 ext. 262
gbewsh@theralase.com